Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
APRE

APRE - Aprea Therapeutics Inc Stock Price, Fair Value and News

$0.74-0.03 (-3.90%)
Market Closed

58/100

APRE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

58/100

APRE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APRE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APRE Price Action

Last 7 days

-17.8%

Last 30 days

21.3%

Last 90 days

-21.3%

Trailing 12 Months

-68.9%

APRE RSI Chart

APRE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

APRE Valuation

Market Cap

4.7M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

9.56

Price/Free Cashflow

-0.35

APRE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

APRE Fundamentals

APRE Revenue

Revenue (TTM)

488.2K

Rev. Growth (Yr)

-99.48%

Rev. Growth (Qtr)

-98.44%

APRE Earnings

Earnings (TTM)

-13.0M

Earnings Growth (Yr)

21.44%

Earnings Growth (Qtr)

8.23%

APRE Profitability

Return on Equity

-119.48%

Return on Assets

-91.04%

Free Cashflow Yield

-287.89%

APRE Investor Care

Shares Dilution (1Y)

16.11%

Diluted EPS (TTM)

-2.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.3M841.0K488.2K0
2024813.1K1.0M1.3M1.5M
2023000583.2K
Get all data in R, Python etc through our Historical Stock Data APIs

About Aprea Therapeutics Inc

APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
 CEO
 WEBSITEaprea.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

Aprea Therapeutics Inc Frequently Asked Questions

APRE is the stock ticker symbol of Aprea Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Aprea Therapeutics Inc is 4.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, APRE's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 9.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APRE PE ratio will change depending on the future growth rate expectations of investors.